Ovarian PRP is marketed to people with low AMH or diminished ovarian reserve as a way to rejuvenate the ovaries. Changes in hormones or follicle counts would not alone prove younger eggs or more live births. Standardized trials, safety and meaningful reproductive outcomes are the tests that matter.
In the landscape of modern fertility treatment, a new term is spreading rapidly: Ovarian PRP (Platelet-Rich Plasma). By concentrating platelets to harness their growth factors and injecting them into the ovary, this therapy seeks to induce tissue regeneration. For women with diminished ovarian reserve (DOR) who have exhausted conventional options, this has been hailed as a potential way to “reawaken the ovary.”
Small studies have reported changes in ovarian-reserve markers after PRP. Uncontrolled signals do not establish a consistent response rate or demonstrate a live-birth benefit.
What does rejuvenation mean?
A change in AMH or follicle count is not proof that new eggs have been created. Mechanism and clinical benefit require separate evidence.
The outcome patients need
Live birth and safety matter more than a promising surrogate marker alone. Reliable comparative evidence remains limited.
The HFEA’s assessment identifies insufficient good-quality evidence for benefit and concerns about safety. Intraovarian PRP should not be described as established fertility care.
The Disconnect Between Clinic and Academy
Limited options can make experimental treatments attractive. That makes transparent discussion of evidence, cost and alternatives particularly important.
However, the risk of “therapeutic optimism” is significant. Terms like “regeneration” or “rejuvenation” can exert a powerful influence on patients’ clinical decisions, potentially overshadowing the limitations of the technology. Given the costs and the time investment, clinicians stress that the distinction between a “promising research avenue” and “established medicine” must be made transparent.
Ovarian PRP remains an experimental proposal. Research participation, clinical options and decisions to continue or stop should be discussed without presenting rejuvenation as a demonstrated result.
Disclaimer: This content is provided for informational purposes, based on reporting on infertility and various public data. Medical judgments and treatment decisions must always be made in consultation with professional medical personnel. Image: AI-generated (ChatGPT, OpenAI) / Visual reference for illustrative purposes only.
Research evidence remains limited
The HFEA identifies insufficient reliable evidence of benefit and safety concerns for intraovarian PRP. HFEA PRP evidence assessment.
Related reading
"The PRP Myth": Why the Scientific Community is Questioning 'Ovarian Rejuvenation'